Hims & Hers Health, Inc. (HIMS) Tops Q3 EPS by 22c; beats on guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Hims and Hers (HIMS) PT Raised to $24 at Citi
November 5, 2024 6:31 AM ESTCiti analyst Daniel Grosslight raised the price target on Hims and Hers (NYSE: HIMS) to $24.00 (from $20.00) while maintaining a Neutral rating.
The analyst comments "HIMS results continue to impress, with another significant beat-and-raise across the board (LINK). Given much of this outperformance was... More
